<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>8
<FILENAME>nuvilex_10k-ex1009.htm
<DESCRIPTION>MEMORANDUM OF UNDERSTANDING
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.9</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>MEMORANDUM OF UNDERSTANDING</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">THIS MEMORANDUM OF
UNDERSTANDING, dated and effective as of January 31, 2011, is made and entered into by and between Nuvilex, Inc., a Nevada corporation
(the &quot;Company&quot;), and Robert F. Ryan, M.S., Ph.D. (&quot;Dr. Ryan&quot;), serving as President and Chief Executive Officer
of Nuvilex, Inc. (NVLX), to set forth compensation terms for the period of one (1) year commencing February 1, 2011 and ending
January 31, 2012 (&quot;Compensation Term&quot;), and provides basic compensation coverage as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Compensation; Incentives; Restricted Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Compensation: Part 1, Sign-On Compensation. For joining Nuvilex as its President and Chief Executive Officer, the Company
shall issue to Dr. Ryan a total of Six Million (6,000,000) restricted shares delivered as Five Hundred Thousand (500,000) restricted
shares on a monthly basis during the Compensation Term defined herein. Such shares are deemed to have been earned on the first
day of each respective month with the Company, commencing on February 1, 2011, and are based on the market closing stock price
on January 28, 2011 of $0.018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Compensation: Part 2, Temporary Salary Equivalent. In lieu of a standard salary, as agreed to by the Chairman and CFO of
Nuvilex and in recognition of the quantity and extent of work performed and as a result of insufficient operating capital in the
Company and until there is sufficient operating capital, the Company shall issue to Dr. Ryan Two Hundred Fifty Thousand (250,000)
restricted shares on a monthly basis from February 1 through May 2011 and Four Hundred Fifteen Thousand (415,000) each month starting
June 1, 2011 through the end of the Compensation Term defined herein. Such shares are deemed to have been earned on the last day
of each respective month and are based on the market closing share price on the last day of such month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Incentives: Part 1. The Company offers the following performance-based incentives to Dr. Ryan as a supplement to his income
during the Compensation Term. The price is based on the closing stock price on the day the performance is completed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">n</FONT></TD><TD STYLE="text-align: justify">Three Million (3,000,000) restricted shares upon completion of the acquisition of SG Austria. These
shares are deemed to have been earned at the Closing of the acquisition of SG Austria, or related entity, by Nuvilex, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">n</FONT></TD><TD STYLE="text-align: justify">Two Million (2,000,000) restricted shares upon completion of the acquisition of Nature Bright,
Wellness Builder, Advanced Medical Sciences, Semorex or other comparable company. These shares are deemed to have been earned at
the Closing of the acquisition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">n</FONT></TD><TD STYLE="text-align: justify">One Million (1,000,000) restricted shares for the commercialization of Oraphyte, Citroxin, or another
of the company's products from the existing product line or addition of any other entity to Nuvilex. These shares are deemed to
have been earned at either the sale of the product to a third party, or through the arrangement of a distribution channel where
sales are imminent or sales to any entity where the sales are anticipated to be greater than $50,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">n</FONT></TD><TD>One Million (1,000,000) restricted shares for the completion of any major event, such as, but not limited to, the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">o&nbsp;&nbsp;&nbsp;IND
filing and issuance,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">o&nbsp;&nbsp;&nbsp;clinical
trial initiation or completion,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">o&nbsp;&nbsp;&nbsp;NDA
filing,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">o&nbsp;&nbsp;&nbsp;NDA
approval,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">o&nbsp;&nbsp;&nbsp;commercialization
or monetization of any new product, or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">o&nbsp;&nbsp;&nbsp;acquisition
of additional products or companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This MEMORANDUM OF UNDERSTANDING, dated and effective as of
January 31, 2011, represents an agreement by and between Dr. Robert F. Ryan, M.S., Ph.D. and Nuvilex, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NUVILEX, INC.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">By: </TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%">/s/ Patricia Gruden</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">/s/ Robert F. Ryan, M.S., PhD</TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Patricia Gruden</TD>
    <TD>&nbsp;</TD>
    <TD>Robert F. Ryan, M.S., PhD</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chairman and CFO</TD>
    <TD>&nbsp;</TD>
    <TD>President and CEO</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
